Teen Becomes First Person Saved by CRISPR Base Editing
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- An unnamed teenage patient was diagnosed with T-cell leukaemia in 2021 at age 13, shortly after COVID lockdown ended, and saw her disease resist both intensive chemotherapy and a bone marrow transplant at Sheffield Children's Hospital before doctors gave her 'weeks, not months.'
- Professor Waseem Qasim organized a trial at Great Ormond Street Hospital that used CRISPR base editing to disguise CAR-T cells so they would no longer attack other T-cells — the obstacle that had made standard CAR-T therapy impossible for T-cell cancers.
- Four weeks after infusion, bone marrow tests found no detectable cancer cells, allowing doctors to proceed with a second bone marrow transplant to restore healthy blood stem cells.
- The patient remains in remission at 17 and is now doing A-levels and learning to drive, though she still lives with an underactive thyroid caused by the months of intensive chemotherapy.
- At a research conference, she met Professor David Liu — the scientist who developed base editing — and now speaks publicly about why continued research funding matters, saying: 'Without it, I wouldn't be here.'
- Her decision to enrol was driven partly by the calculation that even a failed trial could help future patients: 'If it's not gonna help me, it's gonna help someone else,' she told the team.
Why it matters: By showing base-edited CAR-T cells can eliminate T-cell leukaemia when standard CAR-T cannot, this case opens a door for a cancer subtype that previously had no cell-therapy option. The patient herself argues the next milestone is letting future patients skip the brutal chemotherapy regimen she endured and go straight to gene-edited CAR-T treatment.
Ask SkimNews
